Archives

Choose a date range

From To

Choose one or more categories

Categories:



 


CDC awards Leidos $44 million contract

Thursday, July 31, 2014 12:37 PM

Leidos, a national security, health and engineering solutions company, was awarded a prime task order by the Centers for Disease Control and Prevention (CDC) to provide development, support and maintenance of the National Healthcare Safety Network (NHSN).

More... »

WIRB Copernicus Group

Pfizer to buy Baxter’s commercial vaccines business for $635M

Thursday, July 31, 2014 12:35 PM

Baxter International will sell its two commercially marketed vaccines and related production facilities to Pfizer for $635 million in cash.

More... »


Incyte, Genentech ink clinical trial agreement for cancer immunotherapies

Thursday, July 31, 2014 12:33 PM

Incyte has entered into a clinical trial agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, in combination with Genentech's PD-L1 immune checkpoint inhibitor, MPDL3280A, in patients with non-small cell lung cancer (NSCLC).

More... »

Theraclone, Gilead Sciences ink HIV antibodies agreement

Thursday, July 31, 2014 12:31 PM

Theraclone Sciences, a therapeutic antibody discovery and development company, has entered into an agreement with Gilead Sciences, under which Gilead received an exclusive license to develop and commercialize products incorporating Theraclone's broadly neutralizing HIV-antibodies for therapeutic applications in HIV.

More... »

Rho named a Best Place to Work by Triangle Business Journal

Thursday, July 31, 2014 11:36 AM

Rho, a CRO focused on bringing new products to market through a full range of product development services, has been named by Triangle Business Journal a winner of Best Places to Work. The award is part of the publication's annual Best Places to Work Awards program and recognizes Rho’s achievements in creating a positive work environment that attracts and retains employees through a combination of benefits, working conditions and company culture.

More... »

Amy Schulman joins Polaris Partners

Thursday, July 31, 2014 11:24 AM

Polaris Partners has hired biopharmaceutical executive Amy Schulman as a venture partner, based out of Boston, Mass. Schulman, who most recently was general counsel, executive vice president and business unit lead of Pfizer consumer healthcare, will apply decades of experience to the Polaris healthcare portfolio. She also will assume the role of CEO of Arsia Therapeutics, an early stage Polaris-backed company co-founded by Dr. Robert Langer and Polaris partner Alan Crane. 

More... »

Zealand Pharma, Boehringer Ingelheim collaborate on novel peptide medicines

Wednesday, July 30, 2014 12:43 PM

Zealand Pharma, specializing in the discovery, design and development of peptide medicines, and Boehringer Ingelheim have announced a new global R&D collaboration. The collaboration covers a novel therapeutic peptide project from Zealand’s portfolio of preclinical programs. The aim is to develop novel medicines for improved treatment of cardio-metabolic diseases. The target is undisclosed.

More... »

PCI to acquire Penn Pharma

Wednesday, July 30, 2014 12:42 PM

Packaging Coordinators (PCI) has reached a definitive agreement to acquire Penn Pharmaceutical Services.

More... »

Report: Global HIV prevention research down $50M in 2013

Wednesday, July 30, 2014 12:40 PM

According to HIV Vaccines and Microbicides: Resource Tracking Working Group, in 2013 the reported funding for HIV prevention R&D declined by $50 million (4%) compared to 2012, after moderate  increases during the past five years in most HIV prevention R&D research areas, resulting in a total of $1.26 billion.

More... »

NIH programs to focus on emerging areas of science

Wednesday, July 30, 2014 12:40 PM

Scientific areas ripe for targeted investments in technology development and research to improve health are the focus of new programs of the NIH’s Common Fund. The programs include work to facilitate the study of how sugar modifications affect proteins, to understand the arrangement of DNA within cells in four dimensions and to enable the development of new therapies that allow control of organ function through manipulation of nerves.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs